SCHEMBL14744848

SCHEMBL14744848

COC(=O)c1c(O)c(C(C)C)c(-c2ccc3c(ccn3C)c2)[nH]c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 3/20 0.39
KDM4E B2RXH2 1/20 0.38
PRKAA2 P54646 1/20 0.36
PRKAG2 Q9UGJ0 1/20 0.36
PRKAB1 Q9Y478 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35
TUBB8 Q3ZCM7 1/20 0.35
TUBA3E Q6PEY2 1/20 0.35
TUBA1A Q71U36 1/20 0.35
TUBA1C Q9BQE3 1/20 0.35
TUBB6 Q9BUF5 1/20 0.35
TUBB2B Q9BVA1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745201 0.88 PTGER3 (0.40) PTGER3PRKAA2PRKAG2PRKAB1CD274
SCHEMBL14744739 0.84 CD274 (0.37) PTGER3KDM4EPRKAA2PRKAG2PRKAB1
SCHEMBL14746127 0.84 CD274 (0.39) PTGER3KDM4EPRKAA2PRKAG2PRKAB1
SCHEMBL14757885 0.80 PTGER3 (0.39) PTGER3KDM4EPRKAA2PRKAB1TUBB4A
SCHEMBL14758198 0.80 CYP2A6 (0.42) PTGER3ARHSP90AA1HSP90AB1HSP90B1
SCHEMBL16428670 0.77 PTGER3 (0.41) PTGER3ARHSP90AA1HSP90AB1HSP90B1
SCHEMBL14745226 0.77 TUBB4A (0.43) PTGER3PRKAA2PRKAG2PRKAB1TUBB4A
SCHEMBL14746072 0.76 KDM4E (0.37) PTGER3KDM4EUSP2
SCHEMBL14757657 0.74 KDM4E (0.39) PTGER3KDM4EPRKAA2PRKAB1CD274
SCHEMBL17597637 0.74 PRKCI (0.40) PTGER3PRKAA2PRKAG2PRKAB1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP PTGER3 3900/4885KDM4E 4305/4885PRKAA2 2695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.